Masonic cancer center at the university of minnesota receives fda clearance to proceed with phase 1 clinical trial in solid tumors for hcw9218, hcw biologics' novel bifunctional fusion protein

Um cleared to proceed with clinical trial to evaluate hcw9218 in various advanced solid tumors, such as breast, ovarian, prostate, and colorectal cancers um cleared to proceed with clinical trial to evaluate hcw9218 in various advanced solid tumors, such as breast, ovarian, prostate, and colorectal cancers
HCWB Ratings Summary
HCWB Quant Ranking